Trial reportAIDS (London, England)2016
Treatment interruption after 2-year antiretroviral treatment initiated during acute/early HIV in infancy.
Trial report in AIDS (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00428116 (Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya (0-4.5 Month Randomized Controlled Trial)
Who cites it
28 citing papers in PubMed, 39 citations in OpenAlex.
- How past transient viremia shape natural killer cells' antibody-dependent functions in youth with perinatal HIV.iScience · 2026Article
- Recommendations from the 2nd Consensus Workshop on Analytical Treatment Interruption in HIV Research Trials.The lancet. HIV · 2026Article
- Impact of Delayed Early Antiretroviral Therapy Initiation on Treatment Outcomes in Infant Macaques Exposed to SHIVAD8.Viruses · 2025Article
- Autovaccination revisited: potential to boost antiviral immunity and facilitate HIV-1 cure/remission in children.Current opinion in HIV and AIDS · 2025Review
- Intact HIV DNA decays in children with and without complete viral load suppression.PLoS pathogens · 2025Article
- Neuroimaging advances in neurocognitive disorders among HIV-infected individuals.Frontiers in neurology · 2025Review
- Distinct immune profiles in children living with HIV based on timing and duration of suppressive antiretroviral treatment.Virology · 2025Article
- Analytical treatment interruption in children living with HIV: position statement from the EPIICAL consortium.The lancet. HIV · 2024Review
- Article
- Oral Diseases and Oral Health-Related Quality of Life among Kenyan Children and Adolescents with HIV.JDR clinical and translational research · 2023Article
- Similar cortical morphometry trajectories from 5 to 9 years in children with perinatal HIV who started treatment before age 2 years and uninfected controls.BMC neuroscience · 2023Article
- Article
- Article
- Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART.JCI insight · 2021Article
- Caregivers' report of HIV-associated oral manifestations among HIV-unexposed, exposed, and infected Kenyan children.International journal of paediatric dentistry · 2021Article
- Association Between Cytomegalovirus and Epstein-Barr Virus Viremia And Human Immunodeficiency Virus DNA Levels in the Reservoir of Kenyan Infants Receiving Antiretroviral Therapy.The Journal of infectious diseases · 2021Article
- Cortical structural changes related to early antiretroviral therapy (ART) interruption in perinatally HIV-infected children at 5 years of age.IBRO neuroscience reports · 2021Article
- High Plasma Soluble CD163 During Infancy Is a Marker for Neurocognitive Outcomes in Early-Treated HIV-Infected Children.Journal of acquired immune deficiency syndromes (1999) · 2019Article
- Learning From the Exceptions: HIV Remission in Post-treatment Controllers.Frontiers in immunology · 2019Review
- Early antiretroviral therapy in HIV-infected infants: can it lead to HIV remission?The lancet. HIV · 2018Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveTreatment interruption has been well tolerated and durable in some pediatric studies but none have compared treatment interruption with continued antiretroviral treatment (ART) following ART initiation in early HIV. The objective of this study was to compare outcomes in treatment interruption versus continued ART among early-treated infants.
designRandomized trial (OPH-03; NCT00428116).
methodsThe trial included HIV-infected infants who initiated ART at less than 13 months of age, received ART for 24 months, and, if eligible (CD4% >25%, normal growth), were randomized to treatment interruption versus continued ART. Children in the treatment interruption group restarted ART if they met WHO ART-eligibility criteria. During 18-months postrandomization, primary outcomes were incidence of serious adverse events and growth. CD4%, viral load, morbidity, and growth were compared.
resultsOf 140 infants enrolled, 121 started ART, of whom 75 completed at least 24 months ART and 42 were randomized (21 per arm). ART was initiated at median age 5 months and randomization at 30 months. Among 21 treatment interruption children, 14 met ART restart criteria within 3 months. Randomization was discontinued by Data and Safety Monitoring Board due to low treatment interruption durability. At 18 months postrandomization, growth and serious adverse events were comparable between arms; hypercholesteremia incidence was higher in the continued arm (P = 0.03). CD4% and viral load did not differ between arms [CD4% 35% and median viral load undetectable (<150 copies/ml) in both arms, P = 0.9 for each comparison]. No infants had post-treatment viral control.
conclusionShort treatment interruption did not compromise 18-month CD4%, viral control, growth, or morbidity compared with continued ART among infants who started ART in early HIV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.